Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Neurocrine Bioscienc (NBIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 4,315,430
  • Shares Outstanding, K 88,070
  • Annual Sales, $ 15,000 K
  • Annual Income, $ -141,090 K
  • 36-Month Beta 0.42
  • Price/Sales 285.72
  • Price/Cash Flow 0.00
  • Price/Book 17.23

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.75 +9.12%
on 07/11/17
50.75 -3.78%
on 07/27/17
+3.27 (+7.18%)
since 06/27/17
3-Month
41.76 +16.93%
on 06/15/17
55.38 -11.83%
on 05/02/17
-4.76 (-8.88%)
since 04/27/17
52-Week
37.35 +30.74%
on 12/29/16
55.38 -11.83%
on 05/02/17
-1.99 (-3.92%)
since 07/27/16

Most Recent Stories

More News
Notable Thursday Option Activity: NBIX, TPX, THC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Neurocrine Biosciences, Inc. , where a total volume of 3,373 contracts has been traded...

NBIX : 48.83 (-0.35%)
Today's Research Reports on Stocks to Watch: Neurocrine Biosciences, Inc. and Ionis Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / July 25, 2017 / Shares of Neurocrine Biosciences saw a jump in price yesterday, retracing from a loss this past Friday. The company announced a new executive to its management...

NBIX : 48.83 (-0.35%)
IONS : 52.08 (-4.14%)
Neurocrine Biosciences elects Julie Cooke as chief people officer

Biotechnology company Neurocrine Biosciences Inc (NASDAQ:NBIX) reported on Friday the appointment of Julie Cooke as its chief people officer as well as a member of the management committee with effect...

NBIX : 48.83 (-0.35%)
SmarTrend Watching for Potential Pullback in Shares of Neurocrine Biosc After 1.59% Gain

Neurocrine Biosc (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $47.06 to a high of $48.60. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high...

NBIX : 48.83 (-0.35%)
Technical Snapshots for These Generic Drugs Stocks -- Horizon Pharma, Mylan, Neurocrine Biosciences, and Rigel Pharma

If you want a Stock Review on HZNP, MYL, NBIX or RIGL then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. The Generic Drugs market can be segmented...

MYL : 38.49 (-1.79%)
HZNP : 12.66 (-4.24%)
NBIX : 48.83 (-0.35%)
RIGL : 2.35 (-6.00%)
Bayer Starts Phase III Study for Uterine Fibroids' Candidate

Bayer Aktiengesellschaft (BAYRY) announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.

ENZ : 10.97 (-2.83%)
BAYRY : 125.9200 (-3.56%)
NBIX : 48.83 (-0.35%)
ABBV : 71.73 (-1.18%)
Neurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho...

NBIX : 48.83 (-0.35%)
Neurocrine Biosciences Set to Possibly Rebound After Yesterday's Selloff of 9.40%

Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $48.02 to a high of $50.74. Yesterday, the shares fell 9.4%, which took the trading range below the 3-day low...

NBIX : 48.83 (-0.35%)
Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the initial Phase II Tourette syndrome T-Force GREEN study of INGREZZA®(valbenazine), a small molecule VMAT2 inhibitor, did not meet its...

NBIX : 48.83 (-0.35%)
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas....

NBIX : 48.83 (-0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Support & Resistance

2nd Resistance Point 49.71
1st Resistance Point 49.35
Last Price 48.83
1st Support Level 48.62
2nd Support Level 48.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.